Editas Medicine, Inc. (EDIT) vs NeuroPace, Inc. (NPCE)
A side-by-side comparison of Editas Medicine, Inc. and NeuroPace, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EDIT
Editas Medicine, Inc.
$2.83HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
NPCE
NeuroPace, Inc.
$13.04HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Total return — EDIT vs NPCE
growth of $100 · dividends reinvested · last 5yEDIT -91.9% (-39.5%/yr)NPCE -47.0% (-11.9%/yr)NPCE compounded faster over this window
Log scale — wide-divergence pair
EDIT NPCE
EDIT vs NPCE: by the numbers
- •NPCE is the larger company ($445M vs $435M market cap).
- •Both run net losses; NPCE's is the smaller (-19.34% vs -157.32% net margin).
- •NPCE grew revenue faster over the past five years (15.85% vs -10.34% CAGR).
Metrics side by side
Valuation
| Metric | EDIT | NPCE |
|---|---|---|
| P/S ratio | 9.25 | 4.50 |
| P/B ratio | 4.13 | 37.41 |
Profitability
| Metric | EDIT | NPCE |
|---|---|---|
| Gross margin | 100.00% | 79.63% |
| Operating margin | -245.15% | -15.26% |
| Net margin | -157.32% | -19.34% |
| ROE | -70.24% | -160.85% |
| ROIC | -48.61% | -18.95% |
Growth (annualized)
| Metric | EDIT | NPCE |
|---|---|---|
| Revenue CAGR (5Y) | -10.34% | 15.85% |
| Total return CAGR (5Y) | -40.76% | -4.94% |
Frequently asked
- Which has grown faster, EDIT or NPCE?
- Over the past five years, NPCE grew revenue faster — EDIT at a -10.34% CAGR versus NPCE at 15.85%.
- How have EDIT and NPCE total returns compared?
- Over the past 5 years, EDIT delivered -40.76% and NPCE delivered -4.94% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Editas Medicine ROENeuroPace ROEEditas Medicine operating marginNeuroPace operating marginEditas Medicine revenue growthNeuroPace revenue growthEditas Medicine free cash flowNeuroPace free cash flow
Editas Medicine & NeuroPace appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.